Vitamin D receptor modulators

Details Vitamin D receptor modulators Vitamin D receptor modulators

2004-11-16

2009-08-25

Seaman, D. Margaret (Department: 1625)

Organic compounds -- part of the class 532-570 series

Organic compounds

Heterocyclic carbon compounds containing a hetero ring...

Reexamination Certificate

active

07579488

ABSTRACT:
The present invention relates to novel, non-secosteroidal, phenyl-benzofuran compounds with vitamin D receptor (VDR) modulating activity that are less hypercalcemic than 1α,25 dihydroxy vitamin D3. These compounds are useful for treating bone disease and psoriasis.

REFERENCES:
patent: 6218430 (2001-04-01), Allegretto et al.
patent: 6706725 (2004-03-01), Bernardon
patent: 2006/0094778 (2006-05-01), Nagpal et al.
patent: 2006/0135484 (2006-06-01), Nagpal et al.
patent: 2006/0287536 (2006-12-01), Dahnke et al.
patent: 2006/0293385 (2006-12-01), Gajewski et al.
patent: 2007/0105951 (2007-05-01), Gajewski et al.
patent: 2007/0106095 (2007-05-01), Lu et al.
patent: 2007/0149810 (2007-06-01), Lu et al.
patent: 2007/0225377 (2007-09-01), Flatt et al.
patent: WO 2004/048309 (2004-06-01), None
patent: WO 2005/051893 (2005-06-01), None
patent: WO 2006/069153 (2006-06-01), None
patent: WO 2006/069154 (2006-06-01), None
Roger Bouillion, et al., Structure-Function Relationships in the Vitamin D Endocrine System, Endocrine Review, Apr. 2005, pp. 200-257, vol. 16, No.2.
Marcus F. Boehm, et al, Novel nonsecpsteroidal vitamin D mimics exert VDR-modulating activities with less calcium mobilization than 1,25-dihydroxyvitamin D3, Chemistry & Biology, 1999, pp. 265-275, vol. 6, No. 5.
Sunil Nagpal, et al., Vitamin D Analogs: Mechanism of Action and Therapeutic Applications, Current Medicinal Chemistry, 2001, pp. 1661-1679, vol. 8, No. 13.
Boehm, M. F. et al: “Novel Nonsecosteroidal Vitamin D Mimics Exert VDR-Modulating Activities With Less Calcium Mobilization Than 1, 25-Dihydroxyvitamin D3” Chemistry and Biology, Current Biology, London, GB, vol. 6, No. 5, Apr. 6, 1999, pp. 265-275, XP000852987.
Nagpal, S. et al: “Vitamin D Analogs: Mechanism of action and Therapeutic Applications” Current Medicinal Chemistry, Bentham Science Publishers BV, BE, vol. 8 No. 13, Nov. 2001, pp. 1661-1679, XP009003249.
Bouillon R., et al. Endocrine Rev. 1995, 200-257, vol. 16.
Masahiko Inouye, Toshiyuki Miyake, Masaru Furusyo, Hiroyuki Nakazumi: “Molecular recognition of beta-Ribofuranosides by synthetic polypyridine—macrocyclic receptors” J.Am. Chem. Soc. vol. 117, 1995, pp. 12416-12425, XP001206518.
Ping Huang, John Ramphal, James Wei, Congxin Liang, Bahija Jallal, Gerald McMahon and Cho Tang: “Structure-based design and discovery of novel inhibitors of protein tyrosine phosphatases” Bioorganic & Medicinal Chemistry, vol. 11, 2003, pp. 1835-1849, XP001206517.
Swann et al. “Rational Design of Vitamin D3 Analogues Which Selectively Restore Activity to a Vitamin D Receptor Mutant Associated with Rickets”Org. Lett. 2002, p. 1863-3866 vol. 4.
Swann et al. “Structure-Based Design of Selective Agonists for a Rickets-Associated Mutant of the Vitamin D Receptor”J. Am. Chem. Soc. 2002 13795-13805, vol. 124.
Basak, et al., “Comparative effects of calcipotriol and betamethasone 17-valerate solution in the treatment of seborrhoeic dermatitis of the scalp,”European Academy of Dermatology and Venereology JEADV, vol. 15, pp. 77-92 (2001).
Böhm, et al., “Disseminated superficial actinic porokeratosis: Treatment with topical tacalcitol,”Journal of the American Academy of Dermatology, vol. 40, pp. 479-480 (1999).
Cunningham, et al., “Topical calcipotriene for morphea/linear scleroderma,”Journal of the American Academy of Dermatology, vol. 39, pp. 211-215 (1998).
Harrison, “Disseminated superficial actinic porokeratosis responding to calcipotriol,”Clinical Exp. Dermatol, vol. 19, No. 1, p. 95 (1994).
Lin, et al., “The pleiotropic actions of vitamin D,”BioEssays, vol. 26, pp. 21-28 (2003).
Sapadin, et al., “Treatment of Scleroderma,”Arch Dermatology, vol. 138, pp. 99-105 (2002).
Sato, et al., “Epidermal Growth Factor and 1α,25-Dihydroxyvitamin D3Suppress Kipogenesis in Hamster Sebaceous Gland Cells In Vitro,”The Society of Investigative Dermatology, vol. 117, pp. 965-970 (2001).
Zinser, et al., “Vitamin D3receptor ablation sensitizes skin to chemically induced tumorigenesis,”Carcinogenesis, vol. 23, No. 12, pp. 2103-2109 (2002).

Affiliated with

Also associated with

Rating

Vitamin D receptor modulators does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Vitamin D receptor modulators, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Vitamin D receptor modulators will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4074640